Aims & Scope
The Journal of Cellular Biotechnology is a peer-reviewed international journal for advancing research activities in the field of cellular biotechnology. It serves as a medium for the publication of full papers, invited reviews, short communications, technical notes and letters to the Editor-in-Chief on all aspects of cellular biotechnology. This comprises molecular biological topics covering biochemical, chemical, pharmacological or bioprocess engineering aspects, as well as the development of novel biomaterials. Therefore, cellular biotechnology differs from biology, biochemistry, and other basic life sciences by its emphasis on using the knowledge of bioscience to solve important practical problems. Papers presenting information of a multidisciplinary nature - not suitable for publication in a journal devoted to a single discipline - are particularly welcome.
Manuscripts submitted for the Journal of Cellular Biotechnology are expected to cover activities related to molecular diagnostics, the expansion of human primary cells for individualized therapies or drug testing, 2- and 3-dimensional co-culture techniques, cell line validation, tissue engineering, and stem cell biology for the treatment of human pathologies. This includes studies on the design of bioreactors and research on cellular biology and physiology of mammalian human or animal cells in vitro and in vivo, and tissue. Of special interest is the rational manipulation of reactions through metabolic engineering techniques or specific reactor operations that lead to biomaterials with unique properties. Also, biochemical and physiological studies of metabolism and enzymes as relevant for tissue culture cells, investigations at the molecular level including transcription/translation control; design and engineering of products by molecular strategies; engineering of cellular modification and transport systems such as post-translational protein modifications as well as protein and metabolite secretion; molecular strategies of screening for new or modified products (e.g. pharmaceuticals or bioactive compounds). In addition, investigations in preclinical animal experiments are welcome.
The endeavour of the Editor-in-Chief and publisher of the Journal of Cellular Biotechnology is to bring together contributions from those working in various fields related to cell-cell or cell-material interactions all over the world. The editorial board members of the Journal of Cellular Biotechnology are from those countries in Europe, Asia, Australia and America where appreciable work in cellular biotechnology is being carried out. Each editor takes responsibility to decide on the acceptance of a manuscript. He/she is required to have the manuscript appraised by two referees and may be one of them himself. The executive editorial office, to which the manuscripts have been submitted, is responsible for rapid handling of the reviewing process.
Brandenburg University of Technology, Institute of Biotechnology, Molecular Cell Biology, Senftenberg
Brandenburg University of Technology, Senftenberg
Department of Biomechanics, Bulgarian Academy of Sciences, Sofia
Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies, Helmholtz-Centre Geesthacht, Department of Biointerface Engineering, Teltow
Prof. A. Blocki
The Chinese University of Hong Kong, Institute for Tissue Engineering and Regenerative Medicine & School of Biomedical Sciences, Hongkong
Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies, Helmholtz-Centre Geesthacht, Department of Biointerface Engineering, Teltow
Cardiovascular Nanomedicine Unit, Section of Experimental Oncology and Nanomedicine, Department of Otorhinolaryngology, University Hospital Erlangen, Erlangen
Institute for Clinical Radiology, Ludwig-Maximilians-University Hospital Munich-Grosshadern, Munich
Université Claude Bernard, Lyon
Hacettepe University, Istanbul, Turkey
Tehran University of Medical Sciences, School of Advanced Technologies in Medicine, Department of Medical Biotechnology, Tehran
Tianjin University, Key Laboratory of Systems Bioengineering, School of Chemical Engineering and Technology, Tianjin
Central Institute for Biomedical Engineering, Department of Biomaterials, University of Ulm, Ulm
Molecular Biotechnology and Functional Genomics, Technical University of Applied Sciences, Wildau
Birla Institute of Technology and Science, Department of Chemistry, Hyderabad
Mannheim University of Applied Sciences, Mannheim
Heidelberg University, Heidelberg
Ana Santos Silva Herdade
Biochemistry Institute (FMUL), MCastanho Lab, Faculdade de Medicina da Universidade de Lisboa, Avenida Professor Egas Moniz, Lisboa
Martin Luther University of Halle-Wittenberg, Centre for Medical Research, Halle
Faculty of Engineering and Technology, Department of Mechanical Engineering and Materials Science and Engineering, Limassol
Fraunhofer Institute Applied Polymer Research, Potsdam-Golm
Dr. F. Krujatz
Institute of Natural Materials Technology, Technical University Dresden.fv
Catholic Kwandong University, Gangneung
Department of Biomedical Engineering, City College of New York, New York
Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies, Helmholtz-Centre Geesthacht, Department of Biocompatibility, Teltow
Utah State University, School of Veterinary Medicine (WIMU), College of Agriculture and Applied Sciences, Department of Animal, Dairy and Veterinary Sciences (ADVS), Logan, UT
Department of Medicine and Biology, University of Yaroslavl, Yaroslavl
Prof. Dr. N. Nemeth
University of Debrecen Faculty of Medicine, Department of Operative Techniques and Surgical Research.
Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin
Helmholtz-Centre Dresden-Rossendorf, Dresden
Center of Plastic-, Hand- and Reconstructive Surgery, University of Regensburg, Regensburg
Center for Cell Biology and Tissue Engineering, Zurich University of Applied Sciences, Waädenswil
Imperial College, London
Institute of Functional Interfaces, Karlsruhe Institute of Technology (KIT), Karlsruhe
Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon
Green Nanotechnology Center, School of Mechanical Engineering, Korea University, Seoul
Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Hyderabad
Department of Pharmaceutical Sciences, University of Pavia, Pavia
Bio and Process Engineering, Furtwangen University, Schwenningen
Erciyes University, Department of Pharmacology, Kaysere
SUBMISSION OF MANUSCRIPT
Authors are requested to submit their manuscript electronically to the journal’s editorial management system.
Note that the manuscript should be uploaded as one file with tables and figures included. This file can be a Word document, a PDF, or a zip file.
Required files for final submissions
After the article has been accepted, the authors should submit the final version as source files, including a word processor file of the text, such as Word or LateX (If using LaTeX, please use the standard article.sty as a style file and also send a PDF version of the LaTeX file).
TYPES OF CONTRIBUTIONS
Four categories of scientific contributions are accepted for publication: 1) Research Articles
2) Reviews (Mini-Reviews)
3) Short Communications
4) Technical Reports
5) Images in Biotechnology
1) “Research Articles” should have a maximum of 10.000 words, up to 8 display elements (figures/tables), describing the complete study. Longer manuscripts will be considered only if the increased length warranted by the amount of data presented.
2) “Reviews” should have a maximum 8000 words, up to 5 display elements (figures/tables).
“Mini-Reviews” should have a maximum of 4000 words, up to 2 display elements (figures/tables) and will usually be invited by the Editors. Authors wishing to submit a review article should send a brief outline of its contents to the Editor-in-Chief before submittig the manuscript.
3) “Short Communications” should have a maximum of 3000 words, 3 display elements (figures/tables), describing results that are brief, timely and/or of such importance that rapid publication is warranted. These manuscripts should bear the words “Short Communication” immediately above the title on the first page. They should not be subdivided into titled sections but be written in a continuous style.
4) “Technical Reports” should have a maximum of 3000 words, 3 display elements (figures/tables), and describe the development of a novel method or an improvement or noteworthy modification of an already existing technique or platform used in biotechnology. These manuscripts should bear the words “Technical Report” immediately above the title on the first page.
5) The “Images in Biotechnology” article type is not intended for short reports. It should not exceed one page. Up to two authors may be credited with each image. The title of the submission should not comprise more than eight words in total. A separate word file should contain the description of the image (not more than 250 words; not more than 3 references). Asterisks or arrows should hint to details described in the legend.
PREPARATION OF MANUSCRIPTS
Organization of the paper and style of presentation
Manuscripts must be written in English. Authors whose native language is not English are advised to seek the advice of a native English speaker, before submitting their manuscripts.
Peerwith offers a language and copyediting service to all scientists who want to publish their manuscript in scientific peer-reviewed periodicals and books.
Manuscripts should be prepared with wide margins and double spacing throughout, including the abstract, footnotes and references. Every page of the manuscript, including the title page, references, tables, etc., should be numbered.
Headings and subheadings should be numbered and typed on a separate line, without indentation.
The title page should provide the following information:
- Title (should be clear, descriptive and concise)
- Full name(s) of author(s); please indicate who is the corresponding author
- Full affiliation(s) of all authors.
- Present address of author(s), if different from affiliation.
- Running title (45 characters or less, including spaces).
- Complete correspondence address, including telephone number, fax number and e-mail address.
Leave the author information blank if double-blind peer review is wished for, but do include the information in the Submission letter to the editor.
The abstract should be clear, descriptive, self-explanatory and not longer than 200 words, it should also be suitable for publication in abstracting services. The abstract for research papers should follow the “structured abstract” format. Section labels should be in bold uppercase letters followed by a colon, and each section will begin on a new line.
Include a list of 4-10 keywords. These keywords should be terms from the MeSH database.
Footnotes should only be used if absolutely essential. If used, they should be numbered in the text, indicated by superscript numbers and kept as short as possible.
This should outline the context for and purpose of the study.
Materials and Methods
There is no word limit to the materials and methods section, as the journal’s policy is that methodological rigor and reproducibility is of great importance. This section should aim to be sufficiently detailed to enable others with access to the data to reproduce the results.
Mention whether signed informed consent has been obtained.
Compliance and protocol approval
Compliance with guidelines on human experimentation as well as protocol approval by a local Institutional Review Board should be specified.
Compliance with guidelines on animal experimentation as well as protocol approval by the Institutional Animal Care and Use Committee should be specified.
These should be presented in a logical order and summarize the salient findings.
This should link the conclusions with the aims of the study but avoid conclusions not adequately supported by the data.
If there are none, do still include this section and insert "The authors have no acknowledgments".
Specify sources of funding.
If there are none, do still include this section and insert "The authors report no funding".
We ask that for every author, his or her contribution to the manuscript is given, for instance: conception, performance or interpretation of data.
Conflicts of Interest
Please see the section Policy on Conflicts of Interest listed below.
Authors are requested to use the Vancouver citation style. Place citations as numbers in square brackets in the text. All publications cited in the text should be presented in a list of references at the end of the manuscript. List the references in the order in which they appear in the text. Only articles published or accepted for publication should be listed in the reference list. Submitted articles can be listed as (author(s), unpublished data). If an article has a DOI, this should be provided after the page number details. Manuscripts will not be considered if they do not conform to the Vancouver citation guidelines.
References must be listed in Vancouver style:
 Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002;935(1-2):40-6.
 Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.
 Berkow R, Fletcher AJ, editors. The Merck manual of diagnosis and therapy. 16th ed. Rahway (NJ): Merck Research Laboratories; 1992.
 Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGrawHill; 2002. p. 93-113.
 Canadian Cancer Society [homepage on the Internet]. Toronto: The Society; 2006 [updated 2006 May 12; cited 2006 Oct 17]. Available from: www.cancer.ca/.
 Tian D, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. Proc Natl Acad Sci U S A. In press 2002.
 Fletcher D, Wagstaff CRD. Organisational psychology in elite sport: its emergence, application and future. Psychol Sport Exerc. 2009;10(4):427-34. doi:10.1016/j.psychsport.2009.03.009.
Number figures according to their sequence in the text. The text should include references to all figures.
Each figure should have a self-explanatory caption.
Colour figures can be included, provided the cost of their reproduction is paid for by the author.Color figures are free in the electronic version of the journal.
For the file formats of the figures please take the following into account:
- Line art should be have a minimum resolution of 600 dpi, save as EPS or TIFF
- Grayscales (incl photos) should have a minimum resolution of 300 dpi (no lettering), or 500 dpi (when there is lettering); save as tiff
- Do not save figures as JPEG, this format may lose information in the process
- Do not use figures taken from the Internet, the resolution will be too low for printing
- Do not use colour in your figures if they are to be printed in black & white, as this will reduce the print quality (note that in software often the default is colour, you should change the settings)
- For figures that should be printed in colour, please send a CMYK encoded EPS or TIFF
- Figures should be designed with the format of the page of the journal in mind. They should be of such a size as to allow a reduction of 50%.
- On maps and other figures where a scale is needed, use bar scales rather than numerical ones, i.e., do not use scales of the type 1:10,000. This avoids problems if the figures need to be reduced.
Number tables according to their sequence in the text. The text should include references to all tables.
- Each table should have a brief and self-explanatory title.
- Column headings should be brief, but sufficiently explanatory.
- Standard abbreviations of units of measurement should be added between parentheses.
- Vertical lines should not be used to separate columns. Leave some extra space between the columns instead.
- Any explanations essential to the understanding of the table should be given in footnotes at the bottom of the table.
REMEMBER TO INCLUDE
In the cover letter:
- Name, postal address, phone number, fax number and e-mail address of the corresponding author.
- Statement that all authors have contributed to the work, agree with the presented findings, and that the work has not been published before nor is being considered for publication in another journal.
- Statement that procedures involving experiments on human subjects are done in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975.
- Statement that procedures involving experimentation on animal subjects are done in accord with either the guide of the institution in which the experiments were done, or with the National Research Council's guide for the care and use of laboratory animals.
- Full disclosure of conflicts of interest, according to our Policy on Conflicts of Interest (listed below).
In the manuscript:
- Compliance with guidelines on human experimentation as well as protocol approval by a local Institutional Review Board should be specified.
- Compliance with guidelines of animal experimentation as well as protocol approval by the Institutional Animal Care and Use Committee should be specified.
- Statement of all financial and material support for this research and any potential conflicts should also be clearly identified in the Acknowledgment and Conflict of Interest sections. If there is no Conflict-of-Interest then still add this statement.
- Full disclosure of conflicts of interest, according to our Policy on Conflicts of Interest (listed below).
Copyright of your article
Authors submitting a manuscript do so on the understanding that they have read and agreed to the terms of the IOS Press Author Copyright Agreement.
Quoting from other publications
An author, when quoting from someone else's work or when considering reproducing figures or table from a book or journal article, should make sure that he is not infringing a copyright. Although in general an author may quote from other published works, he should obtain permission from the holder of the copyright if he wishes to make substantial extracts or to reproduce tables, plates or other figures. If the copyright holder is not the author of the quoted or reproduced material, it is recommended that the permission of the author should also be sought. Material in unpublished letters and manuscripts is also protected and must not be published unless permission has been obtained. Submission of a paper will be interpreted as a statement that the author has obtained all the necessary permission. A suitable acknowledgement of any borrowed material must always be made.
The corresponding author will receive a PDF proof and is asked to check this proof carefully (the publisher will execute a cursory check only). Corrections other than printer's errors, however, should be avoided. Costs arising from such corrections will be charged to the authors.
This journal publishes all its articles in the IOS Press Pre-Press module. By publishing articles ahead of print the latest research can be accessed much quicker. The pre-press articles are the uncorrected proof versions of the article and are published online shortly after the proof is created. At the same time, the pre-press articles are indexed by PubMed where they appear as [Epub ahead of print]. Pre-press articles are fully citable by using the DOI number.
How to order reprints, a PDF file, journals, or IOS Press books
The corresponding author of a contribution to the journal will receive a complimentary PDF Author’s Copy of the article, unless otherwise stated. This PDF copy is watermarked and for personal use only. A free PDF copy will not be provided for conference proceedings and abstract issues. An order form for a PDF file without watermark, reprints or additional journal copies will be provided along with the PDF proof.
If you wish to order reprints of an earlier published article, please contact the publisher for a quotation. IOS Press, Fax: +31 20 687 0019. Email: firstname.lastname@example.org.
An author is entitled to 25% discount on IOS Press books. See Author's discount (25%) on all IOS Press book publications.
Authors of published articles (non-prepress, final articles) will be contacted by Kudos. Kudos is a service that helps researchers maximize the impact and visibility of their research. It allows authors to enrich their articles with lay metadata, add links to related materials and promote their articles through the Kudos system to a wider public. Authors will receive no more than three emails: one invitation and a maximum of two reminders to register for the service and link the published article to their profile. Using and registering for Kudos remains entirely optional. For more information, please have a look at our authors section.
How to promote your work
Would you like some pointers on how to help your research achieve a wider reach and greater impact? Please consult our Promotional Toolkit for Authors for tips.
Submission of an article is understood to imply that the article is original and unpublished and is not being considered for publication elsewhere. Any possible conflict of interest, financial or otherwise, related to the submitted work must be clearly indicated in the manuscript. Procedures involving experiments on human subjects should be in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975. The author must state compliance in the cover letter and in the Methods section of the article.
Procedures involving experimentation on animal subjects should be in accord with either the guide of the institution in which the experiments were done, or with the National Research Council’s guide for the care and use of laboratory animals. The author must state compliance in the cover letter and in the Methods section of the article. Preferably patients in figures should be unrecognizable. Authors are responsible for obtaining patient permission for use of the material from all recognizable participants in photographs, videos, or other information that may be published in the Journal or on the journal’s website. A statement that permission was granted by the patient must accompany the figure legend. Do not use study participants' names, initials, hospital numbers, or other personal health information anywhere in the manuscript (including figures).
Open access mandates
A growing number of funding agencies now require that research articles they have funded must be made Open Access. This may be either by mandating deposit in repositories after an embargo period or by stipulating that research is published as Open Access. Publishing in the Journal of Cellular Biotechnology complies with all major funding agency requirements.
Green Open Access Publishing in the Journal of Cellular Biotechnology (Self-Archiving)
Authors may self-archive and post the final manuscript version on their own institution, company or funding agency repositories immediately upon acceptance. Alternatively, the author can submit the final published PDF version of the article, which can be ordered from IOS Press. Ordered PDFs will be sent to the author after final publication of the article in an issue. IOS Press holds to no embargo period after final publication.
Authors that are funded by the NIH, Research Councils UK (RCUK) and Wellcome Trust are welcome to deposit their final manuscript version to PubMed Central and Europe PubMed Central immediately upon acceptance. In all cases, a publication reference and URL to the journal’s website must be provided on the first page of the manuscript.
Gold Open Access Publishing in the Journal of Cellular Biotechnology (Open Access Option)
The Open Access option helps authors to comply with major funder mandates. This option allows authors the choice of paying a fee to make their article publicly available on the journal’s website immediately upon publication. By default, all Open Access articles are published under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0). If the article is funded by an organization that mandates CC BY, the authors can request to have their Open Access article published under the terms of the Creative Commons Attribution License (CC BY 4.0).
Policy on Ethics
Journal of Cellular Biotechnology is committed to the highest ethical standards and best practices in publishing and follows the code of conduct for Committee on Publication Ethics/DOAJ and the ICMJE. Any possible conflict of interest, financial or otherwise, related to the submitted work must be clearly indicated in the manuscript.
Journal of Cellular Biotechnology affirms that misconduct, in the form of fabrication, falsification, or plagiarism, jeopardizes the success of the entire scientific endeavor. However, the primary responsibility for considering and resolving allegations of scientific misconduct must be pursued within the individual academic communities and institutions where the scientific work is carried out. Every author of articles or abstracts submitted for publication assumes full responsibility, within the limits of his or her professional competence, for the accuracy of the report. In the case of multiple-authored papers, each author should have made a significant intellectual or practical contribution to the scientific work. Authors submit articles with the understanding that reports must not have been submitted elsewhere.
Questions raised about the conduct of experiments or their presentation will be evaluated preliminarily by the Editors-in-Chief and, if appropriate, in consultation with the Associate Editor handling the review of the manuscript. If deemed appropriate, the matter will be referred to the institution where the scientific work in question was performed. The Journal expects that the matter would be reviewed in accordance with institutional procedures for handling allegations of misconduct. At all stages, every effort should be made to ensure that the process is fair and just, both for those who are accused of misconduct and for those who have raised the issue of scientific misconduct.
In the event that a published article or abstract is to be retracted, a statement of retraction will be published in the Journal of Cellular Biotechnology.
Policy on Use of Animals
Journal of Cellular Biotechnology supports the appropriate and responsible use of animals as experimental subjects. The U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy) and the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Guide) should guide all animal research. Compliance with these guidelines as well as protocol approval by the Institutional Animal Care and Use Committee must be stated in the cover letter and specified in the Methods section of the article. We recommend following the ARRIVE reporting guidelines when documenting animal studies (PLoS Bio 8(6), e1000412, 2010).
- Office of Laboratory Animal Welfare (OLAW) PHS Policy on Humane Care and Use of Laboratory Animals, 2015 (revised March 2015). (http://grants.nih.gov/grants/olaw/olaw.htm)
- Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research, PLoS Biol 8(6): e1000412 (doi:10.1371/journal.pbio.1000412).
Policy on Use of Human Subjects and Informed Consent
Studies involving human subjects must conform with the Federal Policy for the Protection of Human Subjects (United States Office of Science and Technology Policy) and in the Declaration of Helsinki and be approved by a local Institutional Review Board. Compliance with the former and approval by the latter must be stated in the cover letter as well as informed written consent from all human subjects involved in the study, and indicated in the Materials and methods section of the article.
Should the study be exempt from ethics approval, authors need to clearly state the reasons in the declaration statement and in the manuscript. In order to protect subject anonymity, identifying information should not be included in the manuscript unless such information is absolutely necessary for scientific purposes AND explicit approval has been granted by the subjects.
- Declaration of Helsinki. (Adopted in 1964 by the 18th World Medical Assembly in Helsinki, Finland, and revised by the 29th World Medical Assembly in Tokyo in 1975.) In: The Main Issue in Bioethics Revised Edition. Andrew C. Varga, ed. New York: Paulist Press, 1984.
- Federal Policy for the Protection of Human Subjects; Notices and Rules. Federal Register. Vol. 56. No. 117 (June 18, 1991), pp 28002-28007.
- Office for Human Research Protections (OHRP) Human Subject Protections (http://www.hhs.gov/ohrp/)
Policy on Conflicts of Interest
Journal of Cellular Biotechnology requires authors to declare all conflicts of interest, financial or otherwise, independent of relevance to the particular manuscript. All authors must submit a conflicts of interest statement. If there is no conflict of interest to declare, include this section with the statement “The authors have no conflict of interest to report”. Conflicts of interest are herein defined as factors or relationships that could be seen to compromise (or impact) the impartiality of the authors of an article.
Journal of Cellular Biotechnology requests that referees with conflicts of interest, financial or otherwise, declare them when submitting their report and recuse themselves when there is a conflict that may impact a fair and impartial review.
Financial conflicts of interest:
These can include any financial relationship between the authors and any organization that may have a financial interest in their research or financial interests on the part of the authors themselves. This can include, but is not limited to, employment, stocks or shares, patents, research funding, travel or other expenses, lecture fees, or goods or services. Authors should disclose any such relationships: past 2 years, present or anticipated along with any role these organizations may have had in the design, execution or presentation of the study. These can also include financial interests on the part of the authors themselves, such as stocks or shares, patents, or other forms of financial gain.
Non-financial conflicts of interest:
These can include any relationship between the authors and any person or organization that could reasonably be seen to compromise (or impact) the impartiality of the authors of an article. This can include, but is not limited to benefits to relatives, close friends or associates, or organizations that the author has an unpaid relationship with (such as consulting or advisory roles, or providing administrative assistance).
Peer Review Process and Process for Appeals
Journal of Cellular Biotechnology operates a rigorous, timely, blinded peer review process (with an option for double-blinded) by experts in the field. Manuscripts submitted to Journal of Cellular Biotechnology will be assessed for suitability for publication in the journal by the Editors-in-Chief. Manuscripts that are deemed unsuitable may be rejected without peer review by the Editors-in-Chief and/or the Associate Editors and the author will be informed as soon as possible. Manuscripts that are deemed suitable for peer review are forwarded to an Associate Editor with expertise in that area who then recruits appropriate referees (a minimum of two, and usually three or more) for confidential review (identity of referees not revealed to authors). Referee reports are then assessed by the Associate Editor, who makes a decision which is then subject to approval of the Editors-in-Chief. Once approved this decision is then conveyed to the author along with the referee’s reports, but not revealing the identity of the referees.
The initial decision will be one of the following: rejection, acceptance without revision, or potentially acceptable after minor or major revisions. Revised manuscripts will then be appraised by the Associate Editor, who may seek the opinion of referees (prior or new) before making a decision, which again is subject to approval of the Editors-in-Chief. Once approved this decision is then conveyed to the author along with the referee’s reports. Once accepted manuscripts are normally published online without delay as Epub Ahead Of Print (with the date of publication indicated) and appear in the next available print issue.
The Editors-in-Chief has ultimate responsibility for what is published in the journal. Authors may appeal decisions by contacting the Editors-in-Chief. Authors will be informed in writing of the result of their appeal.